129 related articles for article (PubMed ID: 22782165)
1. Ustekinumab for pyoderma gangrenosum.
Kluger N
Arch Dermatol; 2012 May; 148(5):655; author reply 656. PubMed ID: 22782165
[No Abstract] [Full Text] [Related]
2. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
Guenova E; Teske A; Fehrenbacher B; Hoerber S; Adamczyk A; Schaller M; Hoetzenecker W; Biedermann T
Arch Dermatol; 2011 Oct; 147(10):1203-5. PubMed ID: 21680759
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab for peristomal pyoderma gangrenosum.
Fahmy M; Ramamoorthy S; Hata T; Sandborn WJ
Am J Gastroenterol; 2012 May; 107(5):794-5. PubMed ID: 22552250
[No Abstract] [Full Text] [Related]
4. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab.
Goldminz AM; Botto NC; Gottlieb AB
J Am Acad Dermatol; 2012 Nov; 67(5):e237-8. PubMed ID: 23062936
[No Abstract] [Full Text] [Related]
5. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.
Low ZM; Mar A
Australas J Dermatol; 2018 May; 59(2):131-134. PubMed ID: 29205260
[TBL] [Abstract][Full Text] [Related]
6. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review.
Orita A; Hoshina D; Hirosaki K
Clin Exp Dermatol; 2022 Jul; 47(7):1372-1374. PubMed ID: 35298047
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab treatment for pyoderma gangrenosum.
Heffernan MP; Anadkat MJ; Smith DI
Arch Dermatol; 2007 Mar; 143(3):306-8. PubMed ID: 17372094
[No Abstract] [Full Text] [Related]
8. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for treatment of pyoderma gangrenosum.
Pomerantz RG; Husni ME; Mody E; Qureshi AA
Br J Dermatol; 2007 Dec; 157(6):1274-5. PubMed ID: 17916198
[No Abstract] [Full Text] [Related]
10. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
11. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab.
De la Morena F; Martín L; Gisbert JP; Fernández Herrera J; Goiriz R
Inflamm Bowel Dis; 2007 Apr; 13(4):509-10. PubMed ID: 17206663
[No Abstract] [Full Text] [Related]
12. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
13. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis.
Fernández A; Velasco A; Prieto V; Canueto J; Alvarez A; Rodríguez A
Am J Gastroenterol; 2008 Nov; 103(11):2951-2. PubMed ID: 19032482
[No Abstract] [Full Text] [Related]
14. Six patients with pyoderma gangrenosum successfully treated with infliximab.
Mooij JE; van Rappard DC; Mekkes JR
Int J Dermatol; 2013 Nov; 52(11):1418-20. PubMed ID: 22512250
[No Abstract] [Full Text] [Related]
15. Refractory pyoderma gangrenosum treated with infliximab in an infant.
Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
Alkhouri N; Hupertz V; Mahajan L
Inflamm Bowel Dis; 2009 Jun; 15(6):803-6. PubMed ID: 18942748
[No Abstract] [Full Text] [Related]
17. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a refractory pyoderma gangrenosum with risankizumab.
Burgdorf B; Schlott S; Ivanov IH; Dissemond J
Int Wound J; 2020 Aug; 17(4):1086-1088. PubMed ID: 32266771
[No Abstract] [Full Text] [Related]
19. Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).
Jaeger T; Andres C; Grosber M; Zirbs M; Hein R; Ring J; Traidl-Hoffmann C
Eur J Dermatol; 2013; 23(3):408-10. PubMed ID: 23816498
[No Abstract] [Full Text] [Related]
20. [Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
Nybaek H; Jemec GB
Ugeskr Laeger; 2005 Aug; 167(32):2920-1. PubMed ID: 16109221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
